Belhocine Tarik, Spaepen Karoline, Dusart Michelle, Castaigne Catherine, Muylle Kristof, Bourgeois Pierre, Bourgeois Daniel, Dierickx Lawrence, Flamen Patrick
Department of Nuclear Medicine, Jules Bordet Cancer Institute, PET-CT Unit, 1000 Brussels, Belgium.
Int J Oncol. 2006 May;28(5):1249-61.
The clinical added-value of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (18FDG PET) in the management of oncology patients is increasingly documented. In the present review, we discuss both the benefits and the limitations of 18FDG PET in different cancers. Considering the literature data and our own experience, we also indicate the best clinical approach to optimize the use of metabolic imaging in oncology.
18F-氟-2-脱氧-D-葡萄糖正电子发射断层扫描（18FDG PET）在肿瘤患者管理中的临床附加值越来越多地得到记录。在本综述中，我们讨论了18FDG PET在不同癌症中的益处和局限性。考虑到文献数据和我们自己的经验，我们还指出了优化肿瘤代谢成像应用的最佳临床方法。
